Physician profile
John D Morton
NPI 1659471720
$10,105.55
in general payments reported to CMS, 2019-2025
33 companies · $2,187 in 2025
The $2,187 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $495 · 2021: $1,060 · 2022: $1,412 · 2023: $2,530 · 2024: $1,614 · 2025: $2,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,675 · Travel and Lodging: $619 · Education: $37.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,675.36 |
| Travel and Lodging | $618.81 |
| Education | $37.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,594.35 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,633.79 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,245.11 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $724.03 | 2023-2025 | Dupixent |
| Pfizer INC. | $437.62 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $390.65 | 2019-2024 | Linzess |
| Celgene Corporation | $385.55 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $277.20 | 2022-2025 | Sucraid, Sucraid |
| Regeneron Pharmaceuticals, INC. | $271.39 | 2023 | |
| Aimmune Therapeutics, INC. | $261.49 | 2024-2025 | Zenpep, Vowst |
| Takeda Pharmaceuticals U.S.A., INC. | $244.89 | 2019-2025 | Entyvio, Eohilia |
| Braintree Laboratories, INC. | $199.31 | 2019-2025 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $187.43 | 2021-2025 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $145.90 | 2022-2023 | |
| Gilead Sciences, INC. | $145.01 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $113.63 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $103.88 | 2024-2025 | Vegzelma, Zymfentra |
| Ardelyx, INC. | $88.39 | 2022-2025 | Ibsrela |
| Vivus LLC | $87.96 | 2020-2025 | Qsymia, Pancreaze |
| Genzyme Corporation | $77.32 | 2023-2024 | |
| Ferring Pharmaceuticals INC. | $75.09 | 2019-2024 | Rebyota |
| Lilly USA, LLC | $71.46 | 2023-2024 | Omvoh |
| Ethicon US, LLC | $55.41 | 2019 | |
| Evoke Pharma, INC. | $50.68 | 2022-2025 | |
| Pentax of America, INC. | $44.31 | 2025 | Pentax Medical, C2 Cryoballoon, C2 Cryoballoon Focal Controller |
| Phathom Pharmaceuticals, INC. | $36.20 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $30.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.28 | 2023-2024 | Cyltezo |
| Ambu INC. | $23.60 | 2020 | |
| Blueprint Medicines Corporation | $23.50 | 2025 | Ayvakit |
| Medtronic, INC. | $20.92 | 2024 | Endoflip |
| Capsovision, INC. | $17.58 | 2024 | Capsocam Plus |
| Shire North American Group INC | $14.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Morton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.